Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Effect of gradual withdrawal on the rebound sleep disorder after discontinuation of triazolam.

Greenblatt DJ, Harmatz JS, Zinny MA, Shader RI.

N Engl J Med. 1987 Sep 17;317(12):722-8.

PMID:
3306380
2.

Rebound insomnia in normals and patients with insomnia after abrupt and tapered discontinuation.

Roehrs T, Merlotti L, Zorick F, Roth T.

Psychopharmacology (Berl). 1992;108(1-2):67-71.

PMID:
1410148
3.

Rebound insomnia: duration of use and individual differences.

Merlotti L, Roehrs T, Zorick F, Roth T.

J Clin Psychopharmacol. 1991 Dec;11(6):368-73.

PMID:
1770156
4.

Rebound insomnia: a critical review.

Gillin JC, Spinweber CL, Johnson LC.

J Clin Psychopharmacol. 1989 Jun;9(3):161-72. Review.

PMID:
2567741
5.

Rebound insomnia after hypnotic withdrawal in insomniac outpatients.

Hajak G, Clarenbach P, Fischer W, Rodenbeck A, Bandelow B, Broocks A, Rüther E.

Eur Arch Psychiatry Clin Neurosci. 1998;248(3):148-56.

PMID:
9728734
6.

A double-blind, randomized and placebo-controlled study on the polysomnographic withdrawal effects of zopiclone, zolpidem and triazolam in healthy subjects.

Voderholzer U, Riemann D, Hornyak M, Backhaus J, Feige B, Berger M, Hohagen F.

Eur Arch Psychiatry Clin Neurosci. 2001 Jun;251(3):117-23.

PMID:
11697572
7.

Comparison of the short-acting benzodiazepines midazolam and triazolam with placebo.

Hegelbach-Feller DA, Tschopp JM, Christeller S, Fabre J.

Arzneimittelforschung. 1988 Mar;38(3):387-92.

PMID:
3289550
8.

Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic. Zaleplon Clinical Study Group.

Elie R, Rüther E, Farr I, Emilien G, Salinas E.

J Clin Psychiatry. 1999 Aug;60(8):536-44.

PMID:
10485636
9.

Rebound insomnia after only brief and intermittent use of rapidly eliminated benzodiazepines.

Kales A, Manfredi RL, Vgontzas AN, Bixler EO, Vela-Bueno A, Fee EC.

Clin Pharmacol Ther. 1991 Apr;49(4):468-76.

PMID:
2015735
10.

Dose determinants of rebound insomnia.

Roehrs TA, Zorick FJ, Wittig RM, Roth T.

Br J Clin Pharmacol. 1986 Aug;22(2):143-7.

11.

The effects of a single night's dosing with triazolam on sleep the following night.

Mamelak M, Csima A, Price V.

J Clin Pharmacol. 1990 Jun;30(6):549-55.

PMID:
2355105
13.

A comparison of the efficacy, safety and withdrawal effects of zopiclone and triazolam in the treatment of insomnia.

Fleming JA, McClure DJ, Mayes C, Phillips R, Bourgouin J.

Int Clin Psychopharmacol. 1990 Apr;5 Suppl 2:29-37.

PMID:
2201728
14.

Minimal rebound insomnia after treatment with 10-mg zolpidem.

Ware JC, Walsh JK, Scharf MB, Roehrs T, Roth T, Vogel GW.

Clin Neuropharmacol. 1997 Apr;20(2):116-25.

PMID:
9099463
15.

Efficacy and safety of zopiclone and triazolam in the treatment of geriatric insomniacs.

Elie R, Frenay M, Le Morvan P, Bourgouin J.

Int Clin Psychopharmacol. 1990 Apr;5 Suppl 2:39-46.

PMID:
2201729
16.

Rebound insomnia and elimination half-life: assessment of individual subject response.

Bixler EO, Kales JD, Kales A, Jacoby JA, Soldatos CR.

J Clin Pharmacol. 1985 Mar;25(2):115-24. Review.

PMID:
2859304
17.

Comparative hypnotic effects of flurazepam, triazolam, and placebo: a long-term simultaneous nighttime and daytime study.

Mitler MM, Seidel WF, van den Hoed J, Greenblatt DJ, Dement WC.

J Clin Psychopharmacol. 1984 Feb;4(1):2-13.

PMID:
6141188
18.

Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia.

Roth T, Soubrane C, Titeux L, Walsh JK; Zoladult Study Group.

Sleep Med. 2006 Aug;7(5):397-406. Epub 2006 Jul 3.

PMID:
16815744
19.

Polysomnography during withdrawal with clomethiazole or placebo in alcohol dependent patients--a double-blind and randomized study.

Gann H, Feige B, Cloot O, Van Wasen H, Zinzgraf D, Hohagen F, Riemann D.

Pharmacopsychiatry. 2004 Sep;37(5):228-35.

PMID:
15359376
20.

Hypnotic self administration: forced-choice versus single-choice.

Roehrs T, Pedrosi B, Rosenthal L, Zorick F, Roth T.

Psychopharmacology (Berl). 1997 Sep;133(2):121-6.

PMID:
9342777
Items per page

Supplemental Content

Write to the Help Desk